Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Asimadoline (EMD-61753) is a proprietary small molecule therapeutic, originally discovered by Merck KGaA of Darmstadt, Germany. Asimadoline was originally developed to treat peripheral pain such as arthritis. Asimadoline is an orally administered agent that acts as a kappa opioid receptor agonist. It has shown encouraging clinical efficacy for the treatment of IBS in a barostat study in IBS patients and has the potential for treating other gastrointestinal diseases.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | 5 days | $ 67.00 | |
25 mg | 5 days | $ 297.00 | |
1 mL * 10 mM (in DMSO) | 5 days | $ 72.00 |
Description | Asimadoline (EMD-61753) is a proprietary small molecule therapeutic, originally discovered by Merck KGaA of Darmstadt, Germany. Asimadoline was originally developed to treat peripheral pain such as arthritis. Asimadoline is an orally administered agent that acts as a kappa opioid receptor agonist. It has shown encouraging clinical efficacy for the treatment of IBS in a barostat study in IBS patients and has the potential for treating other gastrointestinal diseases. |
Targets&IC50 | κ opioid (human recombinant):1.2nM, κ opioid (Guinea pig):5.6 nM |
Synonyms | EMD-61753 |
Molecular Weight | 414.54 |
Formula | C27H30N2O2 |
CAS No. | 153205-46-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 103.3 mg/mL
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Asimadoline 153205-46-0 Endocrinology/Hormones GPCR/G Protein Neuroscience Opioid Receptor inhibit Inhibitor syndrome allodynia irritable EMD 61753 μ-opioid κ-opioid bowel EMD-61753 EMD61753 δ-opioid diabetic inhibitor